{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:59:39Z","timestamp":1793948379440,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic peritoneal carcinomatosis (PPC), with the worst median overall-survival (mOS), epitomizes the incurability of metastatic cancer. Cancer stem cells (CSCs) underpin this incurability. However, inhibitors of CSC-stemness fail to increase mOS in cancer patients despite preclinical tumor-reduction. This shortfall reinforces that preclinical efficacy should be defined by increased mOS in the presence of cancer comorbidities, CSC-heterogeneity and plasticity. The primary objectives of this study are: to test the dual endothelin-1\/signal peptide receptor, DEspR, as a nodal therapeutic target in PPC, given DEspR induction in anoikis-resistant pancreatic CSCs, and to validate humanized anti-DEspR antibody, hu-6g8, as a potential therapeutic for PPC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used heterogeneous pools of CSCs selected for anoikis resistance from reprogrammed Panc1 and MiaPaCa2 tumor cells (TCs), and adherent TCs reprogrammed from CSCs (cscTCs). We used multiple anti-DEspR blocking antibodies (mAbs) with different epitopes, and a humanized anti-DEspR recombinant mAb cross-reactive in rodents and humans, to test DEspR inhibition effects. We measured DEspR-inhibition efficacy on multiple prometastatic CSC-functions in vitro, and on tumorigenesis and overall survival in a CSC-derived xenograft (CDX) nude rat model of PPC with comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here we show that DEspR, a stress-survival receptor, is present on subsets of PDAC Panc1-TCs, TC-derived CSCs, and CSC-differentiated TCs (cscTCs), and that DESpR-inhibition decreases apoptosis-resistance and pro-metastatic mesenchymal functions of CSCs and cscTCs in vitro. We resolve the DNA-sequence\/protein-function discordance by confirming ADAR1-RNA editing-dependent DEspR-protein expression in Panc1 and MiaPaCa2 TCs. To advance DEspR-inhibition as a nodal therapeutic approach for PPC, we developed and show improved functionality of a recombinant, humanized anti-DEspR IgG4<jats:sup>S228P<\/jats:sup> antibody, hu-6g8, over murine precursor anti-DEspR mabs. Hu-6g8 internalizes and translocates to the nucleus colocalized with cyto-nuclear shuttling galectins-1\/3, and induces apoptotic cell changes. DEspR-inhibition blocks transperitoneal dissemination and progression to peritoneal carcinomatosis of heterogeneous DEspR\u00b1\/CD133\u2009\u00b1\u2009Panc1-derived CSCs in xenografted nude rats, improving mOS without chemotherapy-like adverse effects. Lastly, we show DEspR expression in Stage II-IV primary and invasive TCs in the stroma in PDAC-patient tumor arrays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Collectively, the data support humanized anti-DEspR hu-6g8 as a potential targeted antibody-therapeutic with promising efficacy, safety and prevalence profiles for PPC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08107-w","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:37:57Z","timestamp":1618432677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Humanized anti-DEspR IgG4S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis ratnu\/nu model"],"prefix":"10.1186","volume":"21","author":[{"given":"Christopher M.","family":"Gromisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaiza L. A.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khristine Amber","family":"Pasion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Gromisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Grinstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L. M.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Ruiz-Opazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"9","key":"8107_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm.3327","volume":"19","author":"T Brabletz","year":"2013","unstructured":"Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nat Med. 2013;19(9):1104\u20139. https:\/\/doi.org\/10.1038\/nm.3327.","journal-title":"Nat Med"},{"issue":"1","key":"8107_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"key":"8107_CR3","doi-asserted-by":"publisher","unstructured":"Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, et al. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas. 2011;40(3):415\u201321. https:\/\/doi.org\/10.1097\/MPA.0b013e3182021376.","DOI":"10.1097\/MPA.0b013e3182021376"},{"issue":"1-2","key":"8107_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","volume":"31","author":"KL Sodek","year":"2012","unstructured":"Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012;31(1-2):397\u2013414. https:\/\/doi.org\/10.1007\/s10555-012-9351-2.","journal-title":"Cancer Metastasis Rev"},{"key":"8107_CR5","doi-asserted-by":"publisher","unstructured":"Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Hoshi N, et al. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma. Pancreatology. 2017;17(1):109\u201314. https:\/\/doi.org\/10.1016\/j.pan.2016.11.001.","DOI":"10.1016\/j.pan.2016.11.001"},{"issue":"1","key":"8107_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","volume":"42","author":"I Thomassen","year":"2013","unstructured":"Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42(1):72\u20135. https:\/\/doi.org\/10.1097\/MPA.0b013e31825abf8c.","journal-title":"Pancreas"},{"issue":"1","key":"8107_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.stem.2018.12.009","volume":"24","author":"BC Prager","year":"2019","unstructured":"Prager BC, Xie Q, Bao S, Rich JN. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell. 2019;24(1):41\u201353. https:\/\/doi.org\/10.1016\/j.stem.2018.12.009.","journal-title":"Cell Stem Cell"},{"key":"8107_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2017","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2017;1:313\u201323.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"8107_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.stem.2018.11.017","volume":"24","author":"C Saygin","year":"2019","unstructured":"Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell. 2019;24(1):25\u201340. https:\/\/doi.org\/10.1016\/j.stem.2018.11.017.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"8107_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5483\/BMBRep.2017.50.3.222","volume":"50","author":"K Eun","year":"2017","unstructured":"Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep. 2017;50(3):117\u201325. https:\/\/doi.org\/10.5483\/BMBRep.2017.50.3.222.","journal-title":"BMB Rep"},{"key":"8107_CR11","doi-asserted-by":"publisher","first-page":"e85821","DOI":"10.1371\/journal.pone.0085821","volume":"9","author":"VL Herrera","year":"2014","unstructured":"Herrera VL, Decano JL, Tan GA, Moran AM, Pasion KA, Matsubara Y, et al. DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a \u2018common receptor coordinator\u2019 paradigm. PLoS One. 2014;9:e85821.","journal-title":"PLoS One"},{"issue":"4","key":"8107_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jclinpath-2014-202521","volume":"68","author":"N Cook","year":"2015","unstructured":"Cook N, Brais R, Qian W, Hak CC, Corrie PG. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. J Clin Pathol. 2015;68(4):309\u201313. https:\/\/doi.org\/10.1136\/jclinpath-2014-202521.","journal-title":"J Clin Pathol"},{"key":"8107_CR13","unstructured":"Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, B\u00fcchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3(8):1309\u201316."},{"issue":"13-14","key":"8107_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.lfs.2012.07.034","volume":"91","author":"DE Kohan","year":"2012","unstructured":"Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012;91(13-14):528\u201339. https:\/\/doi.org\/10.1016\/j.lfs.2012.07.034.","journal-title":"Life Sci"},{"key":"8107_CR15","doi-asserted-by":"publisher","unstructured":"Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617\u201322. https:\/\/doi.org\/10.1200\/JCO.2010.28.1386.","DOI":"10.1200\/JCO.2010.28.1386"},{"key":"8107_CR16","unstructured":"National Center for Biotechnology Information Gene Database. https:\/\/www.ncbi.nlm.nih.gov\/gene\/102191832. Accessed 25 Apr 2020."},{"issue":"10","key":"8107_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/01.RES.0000267716.96196.60","volume":"100","author":"N Glorioso","year":"2007","unstructured":"Glorioso N, Herrera VL, Bagamasbad P, Filigheddu F, Troffa C, Argiolas G, et al. Association of ATP1A1 and Dear single-nucleotide polymorphism haplotype with essential hypertension: sex-specific and haplotype-specific effects. Circ Res. 2007;100(10):1522\u20139. https:\/\/doi.org\/10.1161\/01.RES.0000267716.96196.60.","journal-title":"Circ Res"},{"issue":"1","key":"8107_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12867-016-0066-8","volume":"17","author":"VL Herrera","year":"2016","unstructured":"Herrera VL, Steffen M, Moran AM, Tan GA, Pasion KA, Rivera K, et al. Confirmation of translatability and functionality certifies the dual endothelin1\/VEGFsp receptor (DEspR) protein. BMC Mol Biol. 2016;17(1):15. https:\/\/doi.org\/10.1186\/s12867-016-0066-8.","journal-title":"BMC Mol Biol"},{"key":"8107_CR19","doi-asserted-by":"publisher","unstructured":"Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, et al. MiR-204 mediated loss of Mcl-1 results in pancreatic cancer cell death. Mol Cancer. 2013;12(1):105. https:\/\/doi.org\/10.1186\/1476-4598-12-105.","DOI":"10.1186\/1476-4598-12-105"},{"issue":"1","key":"8107_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2016.05.036","volume":"380","author":"S Hannes","year":"2016","unstructured":"Hannes S, Abhari BA, Fulda S. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked. Cancer Lett. 2016;380(1):31\u201328. https:\/\/doi.org\/10.1016\/j.canlet.2016.05.036.","journal-title":"Cancer Lett"},{"issue":"3","key":"8107_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.celrep.2013.10.002","volume":"5","author":"IX Wang","year":"2013","unstructured":"Wang IX, So E, Devlin JL, Zhao Y, Wu M, Cheung VG. ADAR regulates RNA editing, transcript stability, and gene expression. Cell Rep. 2013;5(3):849\u201360. https:\/\/doi.org\/10.1016\/j.celrep.2013.10.002.","journal-title":"Cell Rep"},{"issue":"21","key":"8107_CR22","doi-asserted-by":"publisher","first-page":"12132","DOI":"10.1073\/pnas.211419898","volume":"98","author":"A Herbert","year":"2001","unstructured":"Herbert A, Rich A. The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1. Proc Natl Acad Sci U S A. 2001;98(21):12132\u20137. https:\/\/doi.org\/10.1073\/pnas.211419898.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"8107_CR23","doi-asserted-by":"publisher","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","volume":"16","author":"I Camby","year":"2006","unstructured":"Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006;16(11):137R\u201357R. https:\/\/doi.org\/10.1093\/glycob\/cwl025.","journal-title":"Glycobiology"},{"key":"8107_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/978-1-4939-1396-1_30","volume":"1207","author":"EJ Arnoys","year":"2015","unstructured":"Arnoys EJ, Ackerman CM, Wang JL. Nucleocytoplasmic shuttling of galectin-3. Methods Mol Biol. 2015;1207:465\u201383. https:\/\/doi.org\/10.1007\/978-1-4939-1396-1_30.","journal-title":"Methods Mol Biol"},{"key":"8107_CR25","first-page":"584","volume":"44","author":"D Tarin","year":"1984","unstructured":"Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984;44:584\u20133592.","journal-title":"Cancer Res"},{"issue":"5","key":"8107_CR26","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1007\/s13277-016-4887-3","volume":"37","author":"J Liu","year":"2016","unstructured":"Liu J, Geng X, Li Y. Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumour Biol. 2016;37(5):5715\u201326. https:\/\/doi.org\/10.1007\/s13277-016-4887-3.","journal-title":"Tumour Biol"},{"key":"8107_CR27","doi-asserted-by":"publisher","unstructured":"Fogel EL, Shahda S, Sandrasegaran K, DeWitt J, Easler JJ, Agarwal DM, et al. A multidisciplinary approach to pancreas cancer in 2016: a review. Am J Gastroenterol. 2017;112(4):537\u201354. https:\/\/doi.org\/10.1038\/ajg.2016.610.","DOI":"10.1038\/ajg.2016.610"},{"issue":"1","key":"8107_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12885-018-4439-x","volume":"18","author":"JE Dom\u00ednguez-Mu\u00f1oz","year":"2018","unstructured":"Dom\u00ednguez-Mu\u00f1oz JE, Nieto-Garcia L, L\u00f3pez-D\u00edaz J, Lari\u00f1o-Noia J, Abdulkader I, Iglesias-Garcia J. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer. 2018;18(1):534. https:\/\/doi.org\/10.1186\/s12885-018-4439-x.","journal-title":"BMC Cancer"},{"key":"8107_CR29","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1517\/14712598.5.1.S37","volume":"S1","author":"D Ternant","year":"2005","unstructured":"Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;S1:S37\u201347.","journal-title":"Expert Opin Biol Ther"},{"key":"8107_CR30","doi-asserted-by":"publisher","first-page":"2373868","DOI":"10.1155\/2018\/2373868","volume":"2018","author":"J Ventriglia","year":"2018","unstructured":"Ventriglia J, Petrillo A, Huerta Alv\u00e1ro M, Laterza MM, Savastano B, Gambardella V, et al. Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: a propensity score analysis. Gastroenterol Res Pract. 2018;2018:2373868.","journal-title":"Gastroenterol Res Pract"},{"key":"8107_CR31","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.2147\/OTT.S146228","volume":"11","author":"W Xiang","year":"2018","unstructured":"Xiang W, Yang CY, Bai L. Mcl-1 inhibition in cancer treatment. Onco Targets Ther. 2018;11:7301\u201314. https:\/\/doi.org\/10.2147\/OTT.S146228.","journal-title":"Onco Targets Ther"},{"key":"8107_CR32","doi-asserted-by":"publisher","first-page":"e46303","DOI":"10.15252\/embr.201846303","volume":"19","author":"T Nakahama","year":"2018","unstructured":"Nakahama T, Kato Y, Kim JI, Vongpipatana T, Suzuki Y, Walkley CR, et al. ADAR1-mediated RNA editing is required for thymic self-tolerance and inhibition of autoimmunity. EMBO Rep. 2018;19:e46303.","journal-title":"EMBO Rep"},{"key":"8107_CR33","doi-asserted-by":"publisher","unstructured":"Malinda RR, Zeeberg K, Sharku PC, Ludwig MQ, Pedersen LB, Christensen ST, et al. TGF\u03b2 signaling increases net acid extrusion, proliferation and invasion in Panc-1 pancreatic cancer cells: SMAD4 dependence and link to Merlin\/NF2 signaling. Front Oncol. 2020;10:687. https:\/\/doi.org\/10.3389\/fonc.2020.00687.","DOI":"10.3389\/fonc.2020.00687"},{"key":"8107_CR34","doi-asserted-by":"publisher","unstructured":"Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10(21):7427\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0825.","DOI":"10.1158\/1078-0432.CCR-03-0825"},{"key":"8107_CR35","doi-asserted-by":"publisher","unstructured":"Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, et al. Sinn, \u03b1-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111(10):1917\u201323. https:\/\/doi.org\/10.1038\/bjc.2014.495.","DOI":"10.1038\/bjc.2014.495"},{"key":"8107_CR36","doi-asserted-by":"publisher","unstructured":"Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21(15):3561\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1051.","DOI":"10.1158\/1078-0432.CCR-14-1051"},{"issue":"6","key":"8107_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat Rev Cancer. 2003;3(6):453\u20138. https:\/\/doi.org\/10.1038\/nrc1098.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"8107_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1152\/physiolgenomics.00144.2005","volume":"23","author":"VL Herrera","year":"2005","unstructured":"Herrera VL, Ponce LR, Bagamasbad PD, VanPelt BD, Didishvili T, Ruiz-Opazo N. Embryonic lethality in Dear gene deficient mice: new player in angiogenesis. Physiol Genomics. 2005;23(3):257\u201368. https:\/\/doi.org\/10.1152\/physiolgenomics.00144.2005.","journal-title":"Physiol Genomics"},{"key":"8107_CR39","doi-asserted-by":"publisher","unstructured":"Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018;9(1):5450. https:\/\/doi.org\/10.1038\/s41467-018-07824-4.","DOI":"10.1038\/s41467-018-07824-4"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08107-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T20:39:51Z","timestamp":1618432791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8107"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08107-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal model studies were done in compliance with Boston University IACUC approved protocol AN15160 to V. Herrera and N. Ruiz-Opazo, and in compliance with ARRIVE 2.0 (Additional file-: Supplemental Methods and Materials).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Boston University holds awarded and pending patents on DEspR. Victoria L. M. Herrera, Nelson Ruiz-Opazo, and Francis J. Carr are co-inventors filed by Boston University. These patents comprise the option granted for exclusive license to NControl Therapeutics, Inc. VLMH, NRO, FCJ are scientific co-founders of Abtelum Biomedical Therapeutics, now NControl Therapeutics. VLMH, NRO, FCJ are paid consultants > $10,000 and scientific co-founders, with equity >\u20095%, of NControl Therapeutics, Inc. NControl Therapeutics was not involved in the funding, design, conception, data interpretation, or manuscript preparation. All other co-authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}